GENDER FEATURES OF NONALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH METABOLIC SYNDROME

Evaluation of clinical course and metabolic disorders in men and women with non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MS). Was investigated 164 patients with NAFLD, including 103 men and 61 women. In comparative terms we studied clinical manifestations of NAFLD. All patients NAFLD was verified for the first time. We studied the functional state of the liver function, lipid, carbohydrate and insulin resistance. The study involved 164 patients with NAFLD, including 103 men aged 29 to 64 years and 61 women aged from 44 to 63 years. All the women were examined in a phase of physiological menopause. Patients were divided into 2 groups. In Group 1 included 124 patients with diagnostic criteria for MS, Group 2 consisted of 40 patients without MS. Violations evaluated differentially in men and women. NAFLD is found in most patients with MS in the background. However, a cluster of factors constituting MS significantly more pronounced in men. Main patofi-physiologically factors contributing to the formation of NAFLD, namely TS and-Disley-epidemic appeared to be more significant in men. Perhaps this may be due to bo-Lee early development of liver steatosis in males and younger age compared to women. NAFLD is diagnosed more often in men.

Nonalcoholic fatty liver disease, metabolic syndrome, men, women, dyslipidemia, insulin resistance

1. Avogaro P., Crepaldi G., Enzi G., Tiengo A. Association of hyperlipidemia, diabetes mellitus and mild obesity // Acta Diabetol. Lat. 1967. V. 4. P. :572-590.

2. Reaven G.M. Role of insulin resistance in human disease. Diabetes // 1988 V. 37 P. 1595-1607.

3. Метаболический синдром /Под ред. Г.Е. Ройтберга. М.: Медпресс-информ. 2007.

4. Мамедов М.Н. Необходимо ли определение инсулинорезистентности для диагностики метаболического синдрома в клинической практике? Кардиология. 2005. N 4. C. 92-96.

5. Ивашкин В.Т. Драпкина О.М., Корнеева О.Н. Клинические варианты метаболического син-дрома. М.: Медицинское информационное агенство. 2011.

6. Ивашкин В.Т., Маевская М.В., Павлов Ч.С., Тихонов И.Н., Широкова Е.Н., Буеверов А.О., Драпкина О.М., Шульпекова Ю.О., Цуканов В.В., Маммаев С.Н., Маев И.В., Пальгова Л.К. Клини-ческие рекомендации по диагностике и лечению неалкогольной жировой болезни печени Россий-ского общества по изучению печени и Россиской гастроэнтерологической ассоциации. Рос. жур. гастроэнтерол. гепатол. колопроктол. 2016; 2: 1-20

7. Драпкина О.М., Гацолаева Д.С., Ивашкин В.Т. Неалкогольная жировая болезнь печени как компонент метаболического синдрома. Российские медицинские вести // 2010. N 2. C. 72-78.

8. Browning J.D., Szczepaniak L.S., Dobbins R., Nurenberg P., Horton J.D., Cohen J.C. et al. Prev-alence of hepatic cteatosis in an urban population in the United States: Impact of ethnicity. Hepatology // 2004. V. 40. N 6. P. 1387-1395.

9. Lazo M., Clark J.M. The epidemiology of nonalcoholic fatty liver disease: A global perspective. Semin. Liver Dis. // 2008. V. 28.P. 339-350.

10. Younossi Z.M., Gramlich T., Matteoni C.A., Boparai N., McCoullough A. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin. Gastroenterol. Hepatol. // 2004. V. 2. N 3. P. 262-265.

11. Bedogni G., Miglioli L., Masutti F., Tiribelli C. Prevalence and risk factors for non-alcoholic fatty liver disease: the Dionysos nutrition and liver study // Hepatology. 2005. V. 42 N 1. P. 44-52.

12. Vernon G., Baranova A., Younosi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults // Aliment Pharmacol. Ther. 2011. V. 34. N 2. P. 274-285.

13. Hashimoto E., Tokushigie K. Prevalence, gender, ethnic, and prognosis of NASH. J. Gastroenterol. // 2011. V. 46. N 1. P. 63-69.

14. Алгоритм специализированной медицинской помощи больным сахарным диабетом. /Под ред. И.И. Дедова, М.И. Шестаковой. М., 2015.

15. Py r l K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension // Eur Heart J. 1994. V. 15. P.1300 - 1331. GL.

16. Аронов Д.М., Арабидзе Г.Г., Ахмеджанов Н.М., Балахонова Т.В., Бойцов С.А., Бубнова М.Г. и соавт. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации V пересмотр. М.: 2012.

17. Кривошеев А.Б., Куимов А.Д., Морозов Д.В., Кривошеева И.А., Гмыза О.А. Состояние порфиринового обмена при неалкогольном стеатогепатите //Тер. арх. 2008. T. 80. N 11. C. 64-68.

18. Tarantino G., Saldalamacchia G., Conca P., Arena A. Non-alcoholic Fatty Liver Disease: Further Expression of the Metabolic Syndrome // J. Gastroenterol. Hepatol. 2007. V. 22. N 3. P. 293-303.